Real-World Outcomes With Aflibercept 8 mg
September 7, 2025 • Retinal Diseases Content Hub
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports early anatomical benefit, including a significant reduction in retinal fluid and an average 5-letter improvement in vision in treatment-naïve eyes. Professor Chang notes that the real-world outcomes are consistent with clinical trial results, showing durable fluid resolution with a favorable safety profile.
